51 Results for "

BTB domain

" in MedChemExpress (MCE) Product Catalog:
Products (51)

51 Results for "BTB domain" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-108705
CAS No.: 2166387-65-9
Purity:  99.27%
Research Areas:  

Cancer

BI-3802, a chemical probe, is a highly potent BCL6 degrader and inhibits the Bric-à-brac (BTB) domain of BCL6 with an IC50 of ≤3 nM. BI-3802 induces the polymerization of BCL6 and promotes BCL6 degration depended on E3 ligase SIAH1. BI-3802 has antitumor activity .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-111381
CAS No.: 2166387-64-8
Purity:  99.26%
Target:  

BCL6

Research Areas:  

Cancer

BI-3812, a chemical probe, is a highly efficient BCL6 inhibitor that is capable of suppressing the BTB domain of BCL6, with an IC50 value of ≤ 3 nM, exhibiting antitumor activity .
loading...
    loading...
Cat. No.: HY-172736
CAS No.: 3005272-36-3
Synonyms: BMS-986458
Target:  

PROTACs BCL6 CD20

Research Areas:  

Cancer

Toviblideg (BMS-986458) is a highly selective, orally active cereblon-based BCL6 PROTAC degrader and antitumor agent. Toviblideg selectively degrades BCL6 by binding cereblon to the BTB domain of BCL6, thereby regulating the cell cycle, antiproliferative and interferon signaling pathways, and upregulating the expression and distribution of CD20. Toviblideg modulates the phenotype of follicular helper T cells and reduces circulating tumor DNA levels. The combination of Toviblideg with CD20xCD3 bispecific antibody also enhances the efficiency of T cell tumor infiltration and expansion. Toviblideg induces regression of BCL6-positive tumors and prolongs survival, and it is suitable for research related to B-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, and relapsed/refractory lymphoma .
loading...
    loading...
Cat. No.: HY-161138
Target:  

BCL6 Apoptosis

Research Areas:  

Cancer

WK369 is a novel BCL6 small molecule inhibitor, which exhibits excellent anti-ovarian cancer bioactivity, induces cell cycle arrest and causes apoptosis. WK369 can directly bind to the BCL6-BTB domain and block the interaction between BCL6 and SMRT, leading to the reactivation of p53, ATR and CDKN1A .
loading...
    loading...
Cat. No.: HY-173552
CAS No.: 3067681-36-8
Synonyms: KAT-TCIP
Research Areas:  

Cancer

TCIP3 is a bivalent molecular glue degrader that binds dually to p300/CBP and BCL6. TCIP3 redirects p300 and CBP, thereby activating programmed cell death genes that are normally repressed by the oncogenic driver gene BCL6. TCIP3 induces acetylation of BCL6 and histone tails, inhibits c-MYC transcription. TCIP3 can be used for the research of diffuse large B-cell lymphoma (DLBCL) .
loading...
    loading...
Cat. No.: HY-177755
CAS No.: 2230406-52-5
Target:  

Molecular Glues BCL6

Research Areas:  

Cancer

BCL6-IN-10 (Compound 6) is a selective partially degradable molecular glue inhibitor that targets the BTB domain of BCL6 with an IC50 of 4 nM. BCL6-IN-10 shows anti-proliferative effect in diffuse large B-cell lymphoma (DLBCL) cell lines. BCL6-IN-10 can be used for the research of cancer .
loading...
    loading...
Cat. No.: HY-177756
CAS No.: 2230406-60-5
Target:  

BCL6

Research Areas:  

Cancer

BCL6-IN-11 (Compound 8) is an efficient inhibitor that induces partial degradation of BCL6 with its IC50 value for inhibiting the interaction between BCL6 and its co-inhibitory proteins (such as NCOR1) of 6 nM. BCL6-IN-11 can induce approximately 52% degradation of BCL6 after being treated with 5 μM concentration for 90 minutes, and thus is also classified as a partial degrader. BCL6-IN-11 can be used for the study of lymphoma .
loading...
    loading...
Cat. No.: HY-P10543
CAS No.: 857026-08-5
Target:  

BCL6

Research Areas:  

Cancer

SMRT peptide is one of the co-repressors of BCL6 BTB domain interaction. SMRT peptide binds to the BTB domain of BCL6 and enhances the transcriptional repression function of BCL6. SMRT peptide can be used to study protein-protein interactions .
loading...
    loading...
Cat. No.: HY-170301
Research Areas:  

Others

Keap1-IN-1 (Compound 27) is the inhibitor for Keap1, that covalently modifys the Cys151 site in the BTB domain of KEAP1, and interfers with the interaction between Keap-Nrf. Keap1-IN-1 upregulates the mRNA expression of the antioxidant stress element (ARE)-dependent gene NQO1 with an EC50 of 160 nM. Keap1-IN-1 exhibits cytotoxicity in cell U2OS with an EC50 of 527 nM .
loading...
    loading...
Cat. No.: HY-208744
CAS No.: 2374712-76-0
Target:  

BCL6

Research Areas:  

Cancer

BCL6-IN-14 is a BCL6 inhibitor with a Kd value of 41.1 μM for the BCL6 BTB domain. BCL6-IN-14 inhibits Karpas-422 tumors. BCL6-IN-14 can be used in cancer-related research .
loading...
    loading...
Cat. No.: HY-P701575
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: KBTBD2; BTB And Kelch domain-Containing Protein 1; Prev. BKLHD1; DKFZP566C134; Kelch Repeat And BTB (POZ) domain Containing 2; KIAA1489; Kelch Repeat And BTB domain-Containing Protein 2; Kelch Repeat And BTB domain Containing 2; BTB And Kelch domain Conta
Species:  
Human
Source:  
Sf9 insect cells
loading...
    loading...
Cat. No.: HY-P701576
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: KBTBD2; BTB And Kelch domain-Containing Protein 1; Prev. BKLHD1; DKFZP566C134; Kelch Repeat And BTB (POZ) domain Containing 2; KIAA1489; Kelch Repeat And BTB domain-Containing Protein 2; Kelch Repeat And BTB domain Containing 2; BTB And Kelch domain Conta
Species:  
Human
Source:  
Sf9 insect cells
loading...
    loading...
Cat. No.: HY-P701536
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: ABTB3; BTB (POZ) domain Containing 11; Prev. BTBD11; FLJ33957; ABTB2B; Ankyrin Repeat And BTB/POZ domain-Containing Protein BTBD11; Ankyrin Repeat- And BTB/POZ domain-Containing Protein 3; Ankyrin Repeat And BTB/POZ domain-Containing Protein 3; BTB/POZ Do
Species:  
Human
Source:  
Sf9 insect cells
loading...
    loading...
Cat. No.: HY-P701538
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: BTBD9; KIAA1880; BTB domain Containing 9; BTB/POZ domain-Containing Protein 9; DJ322I12.1; BTB (POZ) domain Containing 9
Species:  
Human
Source:  
Sf9 insect cells
loading...
    loading...
Cat. No.: HY-P701537
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: ABTB3; BTB (POZ) domain Containing 11; Prev. BTBD11; FLJ33957; ABTB2B; Ankyrin Repeat And BTB/POZ domain-Containing Protein BTBD11; Ankyrin Repeat- And BTB/POZ domain-Containing Protein 3; Ankyrin Repeat And BTB/POZ domain-Containing Protein 3; BTB/POZ Do
Species:  
Human
Source:  
Sf9 insect cells
loading...
    loading...
Cat. No.: HY-P701539
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: BTBD9; KIAA1880; BTB domain Containing 9; BTB/POZ domain-Containing Protein 9; DJ322I12.1; BTB (POZ) domain Containing 9
Species:  
Human
Source:  
Sf9 insect cells
loading...
    loading...
Cat. No.: HY-P703490
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: BTB domain-containing protein
Species:  
Others
Source:  
E. coli
loading...
    loading...
Cat. No.: HY-P701577
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: KBTBD6; Kelch Repeat And BTB (POZ) domain Containing 6; Kelch Repeat And BTB domain Containing 6; DKFZp547E1912; Kelch Repeat And BTB domain-Containing Protein 6; Alternative Protein KBTBD6
Species:  
Human
Source:  
Sf9 insect cells
loading...
    loading...
Cat. No.: HY-180166
Target:  

BCL6

Research Areas:  

Cancer

BCL6-IN-12 (Compound 11e) is a BCL6 inhibitor with a Kd of 0.81 μM. BCL6-IN-12 binds to the BTB domain of BCL6. BCL6-IN-12 can be used in the research of diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-P83393
Synonyms: BTB/POZ domain-containing protein KCTD9

Host:  

Rabbit

Application:  

WB, ICC/IF

Reactivity:  

Human

loading...
    loading...